MoneyWorks4Me

The sales is pegged at Rs. 830.83 millions for the December 2024 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 882.81 millions during the year-ago period.The Net Loss for the quarter ended December 2024 is Rs. -93.88 millions as compared to Net Profit of Rs. 187.18 millions of corresponding quarter ended December 2023Operating profit Margin for the quarter ended December 2024 slipped to -83.36% as compared to 252.37% of corresponding quarter ended December 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 830.83 882.81 -5.89 2708.74 2734.04 -0.93 3624.62 3415.64 6.12
Other Income -90.07 168.83 -153.35 346.95 471.10 -26.35 575.52 153.96 273.81
PBIDT -83.36 252.37 -133.03 424.66 844.20 -49.70 1044.32 597.40 74.81
Interest 1.28 1.18 8.47 2.79 2.53 10.28 3.21 4.56 -29.61
PBDT -84.64 251.19 -133.70 421.87 841.67 -49.88 1041.11 592.84 75.61
Depreciation 16.97 16.83 0.83 51.52 49.96 3.12 68.25 85.48 -20.16
PBT -101.61 234.36 -143.36 370.35 791.71 -53.22 972.86 507.36 91.75
TAX -7.73 47.18 -116.38 95.08 166.64 -42.94 218.66 145.61 50.17
Deferred Tax -16.95 10.49 -261.58 53.72 33.91 58.42 42.76 -13.96 -406.30
PAT -93.88 187.18 -150.15 275.27 625.07 -55.96 754.20 361.75 108.49
Equity 57.07 57.07 0.00 57.07 57.07 0.00 57.07 57.07 0.00
PBIDTM(%) -10.03 28.59 -135.10 15.68 30.88 -49.23 28.81 17.49 64.73

Albert David Share Price

807.70 6.95 (0.87%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: